This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
TEM Shares Surge on New AI Breakthrough: Should Investors Jump In?
by Urmimala Biswas
TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.
AZNPositive Net Change IRTCPositive Net Change SOPHPositive Net Change TEMPositive Net Change
artificial-intelligence healthcare medical medical-devices
ISRG's Vessel Sealer Curved for da Vinci Systems Gets FDA Approval
by Zacks Equity Research
Intuitive Surgical wins FDA nod for its Vessel Sealer Curved, boosting the da Vinci system's precision and multifunctional capabilities.
ISRGPositive Net Change CORPositive Net Change ITGRPositive Net Change HIMSNegative Net Change
medical medical-devices
Hims & Hers Stock Surges 90.4% in 3 Months: What's Fueling the Rally?
by Debanjana Dey
HIMS benefits from strong online revenue, subscriber growth, and global expansion moves to fuel its health platform momentum. However, challenges may hurt performance.
TDOCPositive Net Change AMWLNegative Net Change HIMSNegative Net Change
medical medical-devices
Should You Buy Sensata (ST) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
STNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
ZBH Stock Set to Benefit From New Monogram Technologies Buyout Deal
by Zacks Equity Research
Zimmer Biomet eyes long-term gains with the $177M Monogram buyout, aiming to expand its robotic knee surgery offerings by 2027.
BSXNegative Net Change PAHCPositive Net Change ZBHNegative Net Change
medical medical-devices
ANGO Stock Down Despite Q4 Earnings Beat, Gross Margin Declines
by Zacks Equity Research
AngioDynamics beats fourth-quarter fiscal 2025 estimates with strong Med Tech growth amid margin declines and a wider fiscal 2026 loss outlook.
BSXNegative Net Change ANGOPositive Net Change CAHNegative Net Change CORPositive Net Change
earnings medical medical-devices
Veeva Systems' Vault CRM Momentum Builds With Top Biopharma Adoptions
by Harshit Gupta
VEEV sees rising Vault CRM adoption among top biopharma firms, driven by new features, fueling customer migration and growth.
CRMNegative Net Change ORCLPositive Net Change VEEVNegative Net Change
medical medical-devices
Reasons to Add DENTSPLY SIRONA Stock to Your Portfolio Now
by Zacks Equity Research
XRAY gains traction with digital implants, R&D strength, and Q1 margin growth despite softness in Europe.
BSXNegative Net Change XRAYNegative Net Change CORPositive Net Change PAHCPositive Net Change
medical medical-devices
Here's Why You Should Add Inogen Stock to Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
CVSNegative Net Change CORPositive Net Change INGNPositive Net Change WGSPositive Net Change
medical medical-devices
OPRX vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum?
by Indrajit Bandyopadhyay
OPRX is growing faster with rising subscription revenues and strong pharma demand, while GDRX lags due to slower consumer growth.
OPRXPositive Net Change GDRXNegative Net Change
medical medical-devices
Hologic Rides on AI-Powered Breast Health Innovations: What's Next?
by Moumi Mondal
HOLX advances breast health with AI tools like Genius Detection PRO and the upcoming Envision 3D platform.
HOLXPositive Net Change RDNTPositive Net Change GEHCNegative Net Change
medical medical-devices
Should You Continue to Hold Veracyte Stock in Your Portfolio Now?
by Zacks Equity Research
VCYT's Decipher growth and strong cash position bolster its outlook, but Biopharma headwinds and macro risks loom.
CAHNegative Net Change CORPositive Net Change PAHCPositive Net Change VCYTPositive Net Change
medical medical-devices
3 Medical Stocks to Watch as Q2 Earnings Approach: ABT, JNJ, NVS
by Shaun Pruitt
The broader market's historic rebound may make it necessary to consider some defensive positions in the portfolio, and these medical stocks fit the bill ahead of their Q2 reports.
ABTNegative Net Change NVSPositive Net Change JNJPositive Net Change
dividend-investing dividends earnings inflation investing large-cap medical medical-devices pharmaceuticals
Artisan Partners Asset Management (APAM)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
APAMNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ORICPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
3 Medical Info Systems Stocks to Buy Amid AI Boom and Tariff Risk
by Urmimala Biswas
AI momentum and rising demand for digital care put Zacks Medical Info Systems industry stocks like VEEV, TXG and IMDX in focus despite new tariff headwinds.
VEEVNegative Net Change TXGPositive Net Change IMDXNo Net Change
artificial-intelligence medical-devices smart-health
BD Partners With Waters to Build High-Volume Diagnostics Leader
by Zacks Equity Research
BDX collaborates with Waters in a $17.5B deal to form a diagnostics powerhouse targeting $9B in revenues by 2030.
BDXNegative Net Change WATPositive Net Change CORPositive Net Change PAHCPositive Net Change
medical medical-devices
Will Robust MedSurg Performance Fuel Boston Scientific's Q2 Earnings?
by Zacks Equity Research
BSX eyes strong Q2 with MedSurg momentum, solid Cardiovascular growth and benefits from key tech acquisitions.
ABTNegative Net Change BSXNegative Net Change CORPositive Net Change WGSPositive Net Change
earnings medical medical-devices
Old National Bancorp (ONB)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ONBNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Hospital Capex Headwind: Temporary Setback or Lasting Risk for ISRG?
by Indrajit Bandyopadhyay
Intuitive Surgical's global da Vinci growth faces resistance as hospital CapEx tightens abroad, testing leasing and utilization strategies.
MDTNegative Net Change SYKNegative Net Change ISRGPositive Net Change
medical medical-devices
Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms
by Zacks Equity Research
BIO surges 4% as the Stilla acquisition fuels the launch of four ddPCR systems, expanding to 400K+ assay offerings.
BSXNegative Net Change BIOPositive Net Change CORPositive Net Change PAHCPositive Net Change
medical medical-devices
InspireMD Launches CGuard Prime Carotid Stent System in the U.S.
by Zacks Equity Research
NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.
CORPositive Net Change NSPRNegative Net Change ITGRPositive Net Change HIMSNegative Net Change
medical medical-devices
JBT Marel (JBTM) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
JBTMPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, GMS (GMS)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Smart Money Going in Senior Health: Key Stocks in Elderly Care
by Urmimala Biswas
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
ABTNegative Net Change RHHBYPositive Net Change NVOPositive Net Change MDTNegative Net Change SYKNegative Net Change EWPositive Net Change
healthcare medical medical-devices pharmaceuticals